Dernière mise à jour : 02 septembre 2016
Détails
FichiersGeneric Name:
Ramucirumab
État du projet:
Terminé
Domaine thérapeutique:
Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma
Fabricant:
Eli Lilly Canada Inc.
Brand Name:
Cyramza
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0059-000
Strength:
10 mg/mL
Tumour Type:
Gastrointestinal
Indications:
Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma
Funding Request:
As a single agent or in combination with paclitaxel for the treatment of patients with advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma after prior chemotherapy
Review Status:
Complete
Pre Noc Submission:
Yes
Date NOC Issued:
Sponsor:
Eli Lilly Canada Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 02 septembre 2016